
HHS Temporarily Allows Compounding Pharmacies To Make Six Peptides
“The Department of Health and Human Services announces a temporary enforcement discretion policy allowing compounding pharmacies across the U.S. to manufacture six popular peptides while formal FDA rules are considered.”
In medicine and health policy, progress often moves through a maze of red tape and years of study before a single prescription can be filled. But on Wednesday, October 28, a major shift arrived for wellness advocates and compounding pharmacies across America. The Department of Health and Human Services (HHS) announced that compounding pharmacies across the United States can temporarily prepare and distribute six popular peptides, even though these compounds have not yet completed formal approval by the Food and Drug Administration (FDA).
Advertisement
Under the new policy, federal health officials will exercise "enforcement discretion" — choosing not to take legal action against compounding facilities formulating these peptides while formal rule changes move through the pipeline. The six peptides included in the decision are BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. Long discussed in health circles for their potential benefits in tissue recovery, skin vitality, and cellular repair, none of the six currently carry official FDA approval. Under the temporary rules, compounding pharmacies must rigorously certify compound identity and purity while tracking and reporting any side effects.
The decision comes amid a booming online "gray market" where peptides have frequently been sold labeled "for research use only" to bypass regulatory oversight. Health Secretary Robert F. Kennedy Jr. argued that creating a regulated pathway through licensed compounding pharmacies helps protect patients by offering safer, quality-verified alternatives over unregulated online sources. As reported by Reuters, HHS officials noted that President Trump’s administration is prioritizing preventative care and patient safety while cracking down on black-market risks.
Safety guardrails designed by FDA advisory teams — including sourcing raw materials exclusively from FDA-regulated facilities and maintaining strict batch testing — remain in full effect while public comment and permanent rulemaking continue.
Keep your heart and dial tuned to King FM — where faith, family, uplifting music, and national headlines come together 24/7.
Keep it locked on King FM for more from the Gospel world.
Advertisement



